J Korean Soc Echocardiogr.  1995 Jul;3(1):10-16. 10.4250/jkse.1995.3.1.10.

The Clinical Couse and Echocardiographic Findings of Long-Term Angiotensin Converting Enzyme Inhibitor Therapy in the Patients with Severe Chronic Congestive Heart Failure

• Son JW
• Bae SM
• Kam DH
• Kim KD
• Dho HK
• Kim MH
• Kim JS

• KMID: 2410426
• DOI: http://doi.org/10.4250/jkse.1995.3.1.10

Abstract

BACKGROUND
Congestive heart failure is a serious and growing clinical problem. Diuretics and digitalis glycosides remain the traditional regimens of therapy in patients with congestive heart failure, however, angiotensin coverting enzyme(ACE) inhibitors have been added as an important treatment option. Perindopril, a new second generation ACE inhibitor, was added to the patients with severe chronic congestive heart failure who were unresponsive to diuretics and digitalis glycosides to evaluate the clinical and echocardiographic findings. METHOD: The changes of clinical symptoms and signs, echocardiographic findings, serum biochemical examination, ECG, chest X-ray and side effects were evaluated before and 6 months after addition of 2-4mg perindopril in the patients with severe chronic congestive heart failure who were unresponsive to diuretics and digitalis glycosides A total of 63 patients with a man age 57.4±8.7 years, CHF of New York Heart Association(NYHA) more than class III and below 30% of ejection fraction were included after treatment with diuretics and digitalis glycosides more than 3 years.
RESULTS
1) The clinical symptoms of dyspnea, hepatomegaly and pitting edema were significantly improved after the addition of perindopril. 2) The cardiomegaly, lung congestion on chest X-ray, elevated level of serum blook ureanitrogen, aspartate aminotransferase and alanine aminotransferase were significantly improved after the addition of perindopril. 3) In echocardiographic findings, the left ventricular end systolic dimension(55.5±4.8→47.6±4.7mm), the left ventricular end systolic volume(140.4±28.7→82.4±6.4ml), interventricular septal thickness(13.8±3.2→11.6±1.7mm), fractional shortening(18.5±3.4→25.7±3.4%) and ejection fraction(25.1±3.8→38.1±3.2%) were significantly changed. 4) The side effects were 11 cases of dry cough, 6 headache, 4 hypotension, etc,.
CONCLUSION
Perindopril had been shown to be an extremely useful agent in the management of the patients with severe chronic heart failure who were unresponsive to diuretics and digitalis glycosides.

Keyword

Peridonpril; Congestive heart failure

MeSH Terms

Alanine Transaminase
Angiotensins*
Aspartate Aminotransferases
Cardiomegaly
Cough
Digitalis Glycosides
Diuretics
Dyspnea
Echocardiography*
Edema
Electrocardiography
Estrogens, Conjugated (USP)*
Headache
Heart
Heart Failure*
Hepatomegaly
Humans
Hypotension
Lung
Methods
Peptidyl-Dipeptidase A*
Perindopril
Thorax
Alanine Transaminase
Angiotensins
Aspartate Aminotransferases
Digitalis Glycosides
Diuretics
Estrogens, Conjugated (USP)
Peptidyl-Dipeptidase A
Perindopril

Reference

References

1). Smith WM. Epidemiology of congestive heart failure. Am J Cardiol. 55:3A–8A. 1985.

2). Massie BM, Conway M. Survival of patients with congestive heart failure: past, present, and future prospects. Circulation. 75(suppl IV):IV–11-IV-19. 1987.

3). DiCarlo L, Chatterjee K, Parmley WW. Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure. Acute and chronic hemodynamic evaluations. J Am Coll Cardiol. 2:865. 1983.

4). CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study(CONSENSUS). N Engl J Med. 316:1429–35. 1987.

5). The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:293–302. 1991.

6). Gorlin R. Angiotensin converting enzyme inhibitors in the treatment of congestive heart failure. Cardiovasc Rev. Rep. 9:26–30. 1988.

7). The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 259:539–44. 1988.

8). Braunwald E. The Heart Disease. 4th Ed.p. 496. Philadelphia: W B Saunders Co.;1992.

9). Hurst JW, Schlant RC. The Heart. 7th Ed.p. 437. New York: McGraw Hill Co.;1990.

10). Packer M. Therapeutic options in the management of chronic heart failure: Is there a drug of first choice? Circulation. 79:198–204. 1989.

11). Smith TW. Digitalis. Mechanism of action and clinical use. N Engl J Med. 318:358–65. 1988.

12). Lechat P, Garnham SP, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J. (in press).

13). 배종화 • 강홍선 • 김권삼. 김영식 • 송정상. 본태 성 고혈압 환자에서 pe.rindopηl의 강압효과 및 안 전성에 관한 연구 순환기. 21:337–341. 1992.

14). Levy B, Michel JB, Salzmann JL, Azizi M, Piotven P, Camilleri JP, Safar M. Arterial effects of angiotensin converting enzyme inhibition in renovascular and spontaneously hypertensive rats. J Hypertension. 6:823. 1988.

15). Levy B, Michel JB, Salzmann JL, Azizi M, Poitven P, Safar M, Camilleri JP. Effect of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Cir Res. 63:227. 1988.

16). Gosse P, Grellet J, Bonoron S, Tariossel L, Besse P, Eall-Ochio M. Effects of perindopril on left ventricular hypertrophy, coronary blood flow and mechanical performance of papillary muscle in renovascular hypertensive rats. Clin Exper Hypertension. 9:1899. 1987.

17). Asmar RG, Journo HJ, Lacolley PJ. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens. 5:833–839. 1988.

18). Asmar RG, Pannier B, Santoni JP. Reversion of cardiac hypertrophy and reduced arteiral compliance after converting enzyme inhibition in essential hypertension. Circulation. 78:941–950. 1988.

19). Giles TD, Katz R, Sullivan JM. Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol. 13:1240. 1989.

20). Eriksson SV, Offstad J, Kjekshus J. M-mode echocardiography in patients with severe congestive heart failure. Drugs. 39(supp):43. 1990.

21). Swedberg K, Kjekshus J. Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the CONSENSUS trial. Drugs. 39:49. 1990.

22). Pierre D, Isabelle A, Guy L, Isabelle V, Sophie R, Christin W. Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Am J Cardiol. 71:61E. 1993.

23). Sharpe DN, Murphy J, Coxon R, Hannan S. Enalapril in patients with chronic heart failure: a placebo-controlled randomised double blind study. Circulation. 70:271–278. 1984.

24). Cleland JGF, Dargie HJ, Ball SG. Effects of enalapril in heart failure: A double blind study of effects on exercise performance, renal function. Hormones and metabolic state. Br Heart J. 54:305–312. 1985.

25). Luccioni R, Frances Y, Gass R. Evaluation of the dose-effect relationship of a new ACE inhibitor (perindopril) by an automatic blood pressure recorder. Eur Heart J. 9:1131–36. 1988.

26). Lees KR, Reid JC, Scott MG. Captopril versus perindopril: A double-blind study in essential hypertension. J Human Hypertension. 3:17–22. 1989.

27). McEwan JR, Choudry NB, Fuller RW. The effect of sulindac on the abnormal cough reflex associated with dry cough. J Pharmacol Exp Ther. 225:161. 1990.

28). Yeo WW, Ramsay LE. Persistent dry cough with enalapril: incidence depends on method used. J Hum Hypertens. 517–520. 1990.

29). Pierre D, Isabelle A, Guy L, Isabelle V, Sophie R, Christin W. Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Am J Cardiol. 71:66E. 1993.

30). Dickstein K. Practical guidelines for the use of converting enzyme inhibitors in congestive heart failure. Int J Cardiol. 15:1–5. 1987.

31). Hood WB, Youngblood M, Ghali JK, Reid M, Rogers WJ, Howe D, Teo KK. Lejemtel TH for the SOLVD investigators. Initial blood pressure response to enalapril in hospitalized patients(Studies of Left Ventricular Dysfunction SOLVD) Am J Cardiol. 68:1465–1468. 1991.